Synthesis, Anticonvulsant, Antinociceptive Activity and Preliminary Safety Evaluations of Novel Hybrid Imidazolidine‐2,4‐Dione Derivatives with Morpholine Moiety
ChemMedChem · 2025
DOI: 10.1002/cmdc.202400612 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Anna Czopek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna Street, 30-688, Kraków, Poland. Hauptthemen laut MEDLINE: Anticonvulsants, Imidazolidines, Analgesics, Seizures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Science Center, Poland.
Abstract (Originalsprache)
This study aimed to design new hybrid compounds with imidazolidin‐2,4‐dione and morpholine rings as broad spectrum anticonvulsants. To achieve this goal, all compounds were evaluated in animal seizure models, namely the maximal electroshock (MES), the subcutaneous pentylenetetrazole ( sc PTZ), and selected in the 6 Hz (32 mA) tests. The most promising compound, 5‐isopropyl‐3‐(morpholinomethyl)‐5‐phenylimidazolidine‐2,4‐dione ( 19 ), demonstrated broader anticonvulsant activity than phenytoin or levetiracetam, with ED 50 of 26.3 mg/kg (MES), 11.1 mg/kg and 40.9 mg/kg (6 Hz, 32 and 44 mA, respectively). Compared to phenytoin, compound 19 was active in both MES and 6 Hz (32 and 44 mA) tests. It showed nearly 1.5‐fold higher efficacy than levetiracetam in the 6 Hz (32 mA test), but unlike levetiracetam, it was also active in 6 Hz (44 mA) test. Moreover, compound 23 (3‐(morpholinomethyl)‐5,5‐diphenylimidazolidine‐2,4‐dione), displayed similar anticonvulsant efficacy to phenytoin and slightly higher activity than levetiracetam in 6 Hz (32 mA) test. In vitro binding studies showed that compound 23 inhibited weakly sodium and calcium channels, whereas compound 19 did not exhibit this effect. Importantly, both 19 and 23 showed no cytotoxicity in HepG2 cells (MTT test). Unfortunately, these compounds didn′t show antinociceptive activity in the oxaliplatin‐induced neuropathic pain model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna Street, 30-688, Kraków, Poland.
- Corresponding author: Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland.
- Department of Pharmacodynamics, Jagiellonian University Medical College, 9 Medyczna Street, 30-688, Kraków, Poland.
- Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland.
ORCID-Profile: Anna Czopek
Förderung
- National Science Center, Poland
Zitieren
APA
Czopek, A., Byrtus, H., Góra, M., Rapacz, A., Sałat, K., Koczurkiewicz-Adamczyk, P., Pękala, E., Obniska, J., & Kamiński, K. (2025). Synthesis, Anticonvulsant, Antinociceptive Activity and Preliminary Safety Evaluations of Novel Hybrid Imidazolidine‐2,4‐Dione Derivatives with Morpholine Moiety. ChemMedChem. https://doi.org/10.1002/cmdc.202400612
Vancouver
Czopek A, Byrtus H, Góra M, Rapacz A, Sałat K, Koczurkiewicz-Adamczyk P, et al. Synthesis, Anticonvulsant, Antinociceptive Activity and Preliminary Safety Evaluations of Novel Hybrid Imidazolidine‐2,4‐Dione Derivatives with Morpholine Moiety. ChemMedChem. 2025. doi:10.1002/cmdc.202400612
BibTeX
@article{Czopek2025,
author = {Czopek, Anna and Byrtus, Hanna and Góra, Małgorzata and Rapacz, Anna and Sałat, Kinga and Koczurkiewicz-Adamczyk, Paulina and Pękala, Elżbieta and Obniska, Jolanta and Kamiński, Krzysztof},
title = {Synthesis, Anticonvulsant, Antinociceptive Activity and Preliminary Safety Evaluations of Novel Hybrid Imidazolidine‐2,4‐Dione Derivatives with Morpholine Moiety},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202400612}
}
EUVIMED